16:14 , Apr 27, 2018 |  BC Week In Review  |  Company News

UCB buys rights to seizure candidate

UCB S.A. (Euronext:UCB) acquired rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen will receive $150 million up front and is eligible for $220 million in milestones. The...
19:52 , Apr 20, 2018 |  BC Extra  |  Company News

UCB buys rights to seizure candidate

UCB S.A. (Euronext:UCB) acquired rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen will receive $150 million up front and is eligible for $220 million in milestones. The...
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
19:09 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

Paion's remimazolam meets in Phase III trial for procedural sedation

Paion AG (Xetra:PA8) reported data from a Phase III trial in 431 patients undergoing bronchoscopy showing that procedural sedation with remimazolam (CNS 7056, ONO-2745) met the composite primary endpoint vs. both placebo and midazolam of...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

Remimazolam: Phase III started

Paion began a double-blind, U.S. Phase III trial to compare IV remimazolam vs. placebo and open-label midazolam in about 75 high-risk patients undergoing a colonoscopy. Patients will receive 2.5-5 mg initial doses of remimazolam followed...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

Remimazolam: Phase III started

Paion began a double-blind, placebo-controlled, U.S. Phase III trial to compare IV remimazolam vs. midazolam in 460 patients undergoing bronchoscopies. Patients will receive 5 mg remimazolam for induction and 2.5 mg top-ups for maintenance. Paion...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Remimazolam: Phase III started

Paion began a double-blind, placebo-controlled, U.S. Phase III trial to compare IV remimazolam vs. midazolam in about 460 patients undergoing colonoscopy. Patients will receive 5 mg remimazolam for induction and 2.5 mg top-ups for maintenance....
07:00 , Mar 23, 2015 |  BioCentury  |  Product Development

Galapagos' evolution inflection

Data next month for filgotinib will be the first near-term opportunity for Galapagos N.V. to show it can complete its shift from hybrid discovery/service company into a product-focused play. The Janus kinase-1 (JAK-1) inhibitor will...
08:00 , Nov 18, 2013 |  BioCentury  |  Strategy

Shire goes vertical

The proposed $4.2 billion buyout of ViroPharma Inc. fits Shire plc 's long-standing growth through acquisition model, but the new CEO also wants to focus on internal R&D in rare diseases. This deal is an...